Quantcast
Last updated on April 18, 2014 at 16:30 EDT

Latest Multiple drug resistance Stories

2009-04-27 06:00:00

Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. For the first time, European clinicians will have access to a rapid test that can simultaneously identify Mycobacterium tuberculosis (MTB) and resistance to rifampicin (RIF), a common first-line...

2009-04-20 07:30:00

- Wiggins Joins from Biogen Idec - SAN DIEGO, April 20 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that Mark Wiggins has joined the company as Chief Business Officer. Mr. Wiggins comes to Mpex from Biogen Idec, Inc. where he most recently served as Executive Vice President of Business Development, and was a member of the Executive Committee. At Mpex he will be focusing on commercial planning and business development activities related to the company's lead product, MP-376....

2009-04-13 11:30:21

Residents of nursing homes are one of the main reservoirs of anti-microbial resistant bacteria, U.S. researchers said. Study leader Dr. Erin' O'Fallon, a geriatrician at Hebrew Rehabilitation Center and a research fellow in medicine at Harvard Medical School in Boston said that the prevalence of a certain form of drug-resistant bacteria -- multidrug-resistant gram-negative organisms -- far surpassed that of two other common antimicrobial-resistant infections in long-term care facilities....

2009-03-27 09:49:18

A research team at the Scripps Research Institute has obtained the first glimpse of a protein that keeps certain substances, including many drugs, out of cells. The protein, called P-glycoprotein or P-gp for short, is one of the main reasons cancer cells are resistant to chemotherapy drugs. Understanding its structure may help scientists design more effective drugs. The new research was described in the March 27, 2009, issue of the journal Science. "This structure is an important advance and...

2009-03-26 03:30:00

PARIS, March 26 /PRNewswire-FirstCall/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today the appointment of Dr. Karen Bush to the Company's Scientific Advisory Board (SAB). Novexel's SAB is chaired by Dr. David Shlaes who sits on the Company's board. Dr. Bush, who is currently Adjunct Professor at the Department of Biology at Indiana...

2009-03-17 10:48:00

WASHINGTON, March 17 /PRNewswire-USNewswire/ -- Keep Antibiotics Working (KAW) -- a national coalition of health, consumer, agricultural, environmental, humane, and other advocacy groups with more than ten million supporters -- today welcomed the reintroduction of a bill that would help combat the antibiotic resistance crisis by targeting the overuse of antibiotics important to human medicine in animal agriculture. The legislation, "The Preservation of Antibiotics for Medical Treatment...

2009-03-04 06:00:00

Product Candidate NVC-422 Demonstrates Ability to Treat Subcutaneous Infections EMERYVILLE, Calif., March 4 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a clinical stage biopharmaceutical company, today announced that new preclinical data related to NVC-422, the lead molecule in NovaBay's, proprietary Aganocide(R) class of compounds, will be presented at the American Academy of Dermatology (AAD) 67th Annual Meeting in San Francisco during March 6-10, 2009....

2009-02-10 07:30:00

SAN DIEGO, Feb. 10 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that it has completed a $27.5 million initial closing of a Series D financing led by Investor Growth Capital. Other participating investors include RiverVest Venture Partners, as well as existing investors SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners. These investors have made commitments to additional closings that could bring the total Series D financing to $40.0 million. Mpex's...

2009-01-08 18:29:00

BOSTON, Jan. 8 /PRNewswire-USNewswire/ -- The Alliance for the Prudent Use of Antibiotics (APUA) strongly opposes the new marketing campaigns by Wal-Mart, Stop and Shop, Publix, and other large chains, to provide free prescribed antibiotics to customers. These offers are portrayed as cost-saving but they will actually lead to increased costs in the form of treatment failures because of antibiotic resistance. While the public's need for affordable healthcare is indisputable, providing free...

2008-12-18 10:01:13

Case Western Reserve University School of Medicine scientist leads comparative analysis of six genomes of Acinetobacter baumanniiThe recent emergence of multidrug resistance (MDR) in Acinetobacter baumannii, a bacteria that causes infections primarily among seriously ill patients in the intensive care unit who may have reduced immune systems, has raised concern in health care settings worldwide. When comparing the genome sequence of three MDR A. baumannii isolates and three drug-susceptible...